1. Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression.
- Author
-
Bradley MA, Xiong-Fister S, Markesbery WR, and Lovell MA
- Subjects
- Aged, Aged, 80 and over, Animals, Biomarkers metabolism, Cells, Cultured, Cerebral Cortex metabolism, Cerebral Cortex pathology, Female, Humans, Male, Neurons metabolism, Neurons pathology, Rats, Up-Regulation physiology, Aldehydes metabolism, Alzheimer Disease metabolism, Alzheimer Disease pathology, Disease Progression
- Abstract
Multiple studies have demonstrated elevations of α, β-unsaturated aldehydes including 4-hydroxynonenal (HNE) and acrolein, in vulnerable regions of mild cognitive impairment (MCI), preclinical Alzheimer's disease (PCAD), and late stage Alzheimer's disease (LAD) brain. However, there has been limited study of a third member, 4-hydroxyhexenal (HHE), a diffusible lipid peroxidation product of the ω-3 polyunstataturated fatty acids (PUFAs). In the present study levels of extractable and protein-bound HHE were quantified in the hippocampus/parahippocampal gyrus (HPG), superior and middle temporal gyri (SMTG), and cerebellum (CER) of MCI, PCAD, LAD, and normal control (NC) subjects. Levels of extractable and protein-bound HHE were increased in multiple regions in the progression of Alzheimer's disease (AD). Extractable HHE was significantly elevated in the hippocampus/parahippocampal gyrus (HPG) of PCAD and LAD subjects and protein-bound HHE was significantly higher in MCI, PCAD, and LAD HPG. A time- and concentration-dependent decrease in survival and a concentration-dependent decrease in glucose uptake were observed in primary cortical cultures treated with HHE. Together these data support a role for lipid peroxidation in the progression of Alzheimer's disease., (Copyright © 2012 Elsevier Inc. All rights reserved.) more...
- Published
- 2012
- Full Text
- View/download PDF